Imaging EGFR-positive cancers using a new PET method
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET)
This study is testing a new imaging method to see if it can help doctors spot certain cancers that have a lot of a protein called EGFR, which could help identify patients who might benefit from specific cancer treatments.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 14 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Saskatchewan Academic / other |
| Drugs / interventions | nimotuzumab |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Trial ID | NCT04235114 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the use of 89Zr-DFO-nimotuzumab for non-invasive imaging of cancers that over-express the Epidermal Growth Factor Receptor (EGFR), such as lung and colorectal cancers. By utilizing Positron Emission Tomography (PET) and Computerized Tomography (CT), the study aims to determine the feasibility of visualizing EGFR-positive tumors, which could help identify patients likely to benefit from anti-EGFR treatments. The trial will assess the accumulation of the imaging agent in tumors and establish the optimal timing for imaging. This approach seeks to improve the reliability of EGFR expression monitoring compared to existing invasive methods.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with EGFR-positive cancers and tumors measuring at least 1.5 cm.
Not a fit: Patients who are unable to tolerate 60 minutes of PET imaging or those who have previously received anti-EGFR antibody treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to more accurate and less invasive identification of patients who would benefit from targeted anti-EGFR therapies.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in non-invasive imaging techniques for cancer detection.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female between 18 and 80 years old. * EGFR-positive cancer defined by a board certified pathologist * Primary or metastatic lesion size \>= 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination. * Able to give informed consent. * Not currently pregnant or nursing: If female subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for \> 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test is negative when taken within the 24 h before administration of 89Zr-DFO-nimotuzumab. * WHO performance status of 0 - 2 * Patients naïve to anti-EGFR antibodies treatment. Exclusion Criteria: * Unable to tolerate 60 min of PET imaging per session.
Where this trial is running
Saskatoon, Saskatchewan
- Royal University Hospital — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Study coordinator: Rajan Rakheja, MD
- Email: rajan.rakheja@gmail.com
- Phone: 306-655-2932
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.